Table 1.
Demographics of participants in the single- and multiple-dose studies
| Parameter | Single-dose study (all periods; n = 24) | Multiple-dose study |
||
|---|---|---|---|---|
| Placebo (n = 10) | Oseltamivir 100 mg i.v. (n = 19a) | Oseltamivir 200 mg i.v. (n = 20) | ||
| No. (%) of volunteers by: | ||||
| Gender (male) | 23 (96) | 5 (50) | 9 (47) | 16 (80) |
| Race | ||||
| Caucasian | 22 (92) | 8 (80) | 15 (79) | 10 (50) |
| Black | 1 (4) | 2 (20) | 4 (21) | 9 (45) |
| Oriental | 1 (4) | |||
| American Indian/Alaska Native | 1 (5) | |||
| Age (yr) | ||||
| Mean ± SD | 31.3 ± 8.49 | 28.1 ± 6.19 | 28.3 ± 6.97 | 30.2 ± 7.73 |
| Median (range) | 33.0 (18–52) | 28.0 (19–36) | 27.0 (18–43) | 28.0 (19–44) |
| Body wt (kg) | ||||
| Mean ± SD | 74.70 ± 10.08 | 78.88 ± 11.85 | 75.22 ± 17.73 | 80.02 ± 12.84 |
| Median (range) | 72.20 (55.8–90.9) | 72.60 (66.5–98.6) | 72.20 (51.0–115.5) | 77.30 (54.5–105.4) |
| Ht (cm) | ||||
| Mean ± SD | 176.9 ± 7.17 | 170.5 ± 13.17 | 169.1 ± 9.27 | 174.8 ± 6.01 |
| Median (range) | 179.0 (158–191) | 170.5 (149–194) | 167.0 (157–184) | 175.5 (160–186) |
| BMI | ||||
| Mean ± SD | 23.83 ± 2.52 | 27.18 ± 3.25 | 26.10 ± 4.57 | 26.16 ± 3.85 |
| Median (range) | 24.10 (19.1–29.3) | 26.74 (24.10–33.72) | 25.55 (17.10–34.24) | 25.05 (20.29–33.49) |
| Estimated creatinine clearance | ||||
| Mean ± SD | 143.53 ± 23.58 | 143.26 ± 21.87 | 140.87 ± 31.61 | 137.90 ± 34.21 |
| Median (range) | 146.53 (101.2–185.7) | 132.22 (121.86–178.08) | 137.57 (90.03–202.21) | 130.98 (95.78–220.24) |
a
n = 18 for estimated creatinine clearance.